Methods for the treatment, diagnosis, and prognosis of cancer

• US 20060160762A1
• Filed: 12/13/2005
• Published: 07/20/2006
• Est. Priority Date: 12/13/2004
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Mangold, Ursula, Kim, Sonia, Zetter, Bruce R.
• Application Number:
  US11/301,592
• Publication Number:
  US 20060160762A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/6897 involving reporter genes operably linked to promoters
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry
• CPC Class Codes: G01N 33/6851 Methods of protein analysis involving laser desorption ionisation mass spectrometry

Abstract

We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment of cancer, the use of antizyme inhibitor for the diagnosis and prognosis of cancer, and methods for identifying novel cancer treatments.

Claims

1. A method for treating cancer comprising administering to a subject in need thereof an effective amount of a pharmaceutical comprising an active agent or compound which inhibits antizyme inhibitor, and a pharmaceutically acceptable carrier or diluent.

2. The method of claim 1, wherein the cancer is selected from the group consisting of prostate cancer, lung carcinoma, breast carcinoma, thyroid carcinoma, brain cancers (cerebellum, medulloblastoma, astrocytoma, ependymoma, glioblastoma), pancreatic carcinoma, ovarian carcinoma, eye cancer (retinoblastoma), muscle (rhabdosarcoma), lymphoma, stomach cancer, liver cancer, colon cancer, kidney cancer, and skin cancer.

4. The method of claim 1, wherein the agent or compound is selected from the group consisting of DNA, RNA, an RNA interfering agent, PNA, a small organic molecule, a natural product, a protein, an antibody, a peptide and peptidomimetic.

7. The method of claim 1, wherein the agent or compound inhibits the activity of the antizyme inhibitor.

3. The method of claim 3, wherein the cancer is selected from the group consisting of stomach cancer, lung cancer, liver cancer, brain cancer, and adrenal cancer.

5. The method of claim 5, wherein the RNA interfering agent is a double-stranded, short interfering RNA (siRNA).

6. The method of claim 6, wherein said siRNA inhibits antizyme inhibitors by transcriptional silencing expression of the antizyme inhibitors.

8. A method for screening for a compound or agent useful for the treatment of cancer, comprising:

a) providing a cell comprising a reporter plasmid comprising a nucleic acid sequence encoding antizyme inhibitor;

b) contacting said cell with a test compound or agent;

c) comparing the level of reporter expression in the presence of the test compound with the level of reporter expression in a control sample in the absence of the test compound; and

d) determining whether or not the test compound increases or decreases the level of reporter expression, wherein a decrease in the level of reporter expression indicates the compound or agent is an antizyme inhibitor.

9. A method for screening for a compound or agent useful for the treatment of cancer, comprising:

screening a library of candidate compounds to identify those compounds which inhibit antizyme inhibitor.

10. A method of diagnosing cancer in a patient, comprising:

a) determining the level of antizyme inhibitor in the test sample; and

b) comparing the level of antizyme inhibitor or its variants in the test sample with the level of antizyme inhibitor present in a normal control sample;

wherein a higher level of antizyme inhibitor in the test sample as compared to the level in the normal control sample is indicative of cancer.

11. The method of claim 10, wherein said test sample and said normal control sample are selected from the group consisting of blood, tissue, serum, stool, urine, sputum, cerebrospinal fluid, nipple aspirates, and supernatant from cell lysate.

12. The method of claim 10, wherein the cancer is selected from the group consisting of prostate cancer, stomach cancer, lung cancer, liver cancer, brain cancer, and adrenal cancer.

13. The method of claim 12, wherein the mRNA is detected by use of polymerase chain reaction.

14. The method of claim 12, wherein the mRNA is detected by Northern blot analysis by hybridizing mRNA from said test sample or said control sample to an antizyme inhibitor nucleotide probe.

15. The method of claim 12, wherein the mRNA is detected by DNA microarray analysis.

16. The method of claim 10, wherein the level of antizyme inhibitor is measured by measuring the levels of antizyme inhibitor protein.

18. The method of claim 16, wherein the method of measuring the level of antizyme inhibitor comprises the steps of:

a) contacting a sample or preparation thereof with an antibody or antibody fragment which selectively binds antizyme inhibitor; and

b) detecting whether said antibody or said antibody fragment is bound by said sample and thereby measuring the levels of antizyme inhibitor present.

19. The method of claim 18 wherein said antibody, or said antibody fragment, is detectably labeled.

17. The method of 16, wherein the antizyme inhibitor protein level is measured by Immunoblotting or ELISA.

20. A method for prognostic evaluation of a patient suspected of having or having cancer comprising:

a) determining the level of antizyme inhibitor in a test sample obtained from a patient;

b) comparing the level determined in step (a) to a range of antizyme inhibitor known to be present in a biological sample obtained from a normal patient that does not have cancer; and

c) determining the prognosis of said patient based on the comparison of step (b), wherein a high level of antizyme inhibitor in step (a) indicates an aggressive form of cancer and therefore a poor prognosis.

21. A kit for measuring antizyme inhibitor levels comprising separate vials containing antibodies, or antibody fragments, which selectively bind human antizyme inhibitor.